Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1

Jankun,Jerzy; Skrzypczak-Jankun,Ewa

doi:10.3892/etm_00000090

Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1

Authors:
- Jerzy Jankun
- Ewa Skrzypczak-Jankun
View Affiliations

Affiliations: Urology Research Center, Department of Urology, The University of Toledo - Health Science Campus, Toledo, OH 43614, USA. jerzy.jankun@utoledo.edu
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000090
Pages: 575-577

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we present a 60-year-old woman of American Indian descent with a life-long history of bleeding diathesis. She had a history of recurrent and prolonged bleeding such as mild epistaxis, gingival bleeding and microscopic hematurias. She also experienced a severe bleeding event after surgery. The patient had a large family with a history of a tendency of bleeding, severe in some cases. Hemostatic screening studies revealed no abnormalities, which could explain the bleeding tendency. Clot formation of sodium-citrated blood was analyzed by thromboelastography, which suggested a low platelet count or plasminogen activator inhibitor-1 (PAI-1) deficiency. However, her platelet count was slightly elevated. Subsequent sequencing of the PAI-1 gene revealed a heterozygous Ala15Thr mutation in the signal peptide. This type of deficiency is related to dynamics of PAI-1 secretion rather than its low levels or activity. We concluded that the PAI-1 mutation was likely the etiology of the bleeding diathesis in this patient.

View Figures

View References

1.	Lopes C, Dina C, Durand E and Froguel P: PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia. 46:1284–1290. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Zhang ZY, Wang ZY, Dong NZ, Bai X, Zhang W and Ruan CG: A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. Blood Coagul Fibrinolysis. 16:79–84. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Fay WP, Parker AC, Condrey LR and Shapiro AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 90:204–208. 1997.PubMed/NCBI
4.	Evans PA, Hawkins K, Lawrence M, Barrow MS, Williams PR and Williams RL: Studies of whole blood coagulation by oscillatory shear, thromboelastography and free oscillation rheometry. Clin Hemorheol Microcirc. 38:267–277. 2008.PubMed/NCBI
5.	Gallimore MJ, Harris SL, Tappenden KA, Winter M and Jones DW: Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost. 3:2506–2513. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Carr ME Jr, Krishnamurti C and Alving BM: Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis. Thromb Haemost. 67:106–110. 1992.PubMed/NCBI
7.	Sugiki M, Maruyama M, Yoshida E, Mihara H, Kamiguti AS and Theakston DG: Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom. Toxicon. 33:1605–1617. 1995. View Article : Google Scholar : PubMed/NCBI
8.	Jankun J, Aleem AM, Selman SH, et al: Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med. 20:683–687. 2007.
9.	Kohro S, Yamakage M, Omote T and Namiki A: In vitro effects of propofol on blood coagulability and fibrinolysis by the use of thromboelastograph technique. Acta Anaesthesiol Scand. 43:217–219. 1999. View Article : Google Scholar : PubMed/NCBI
10.	Agren A, Wiman B and Schulman S: Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis. 18:657–660. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Perkowska A, Elhasade A, Durlik M, et al: The effect of chronic allograft rejection on plasma regulators of fibrinolysis. Ann Transplant. 7:44–51. 2002.PubMed/NCBI
12.	TEG 5000 User's Manual Version 4.2 Software. Haemoscope Corporation 2006.
13.	Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH and Skrzypczak-Jankun E: Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacol Rep. 61:673–680. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Mehta R and Shapiro AD: Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 14:1255–1260. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Schleef RR, Higgins DL, Pillemer E and Levitt LJ: Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 83:1747–1752. 1989. View Article : Google Scholar : PubMed/NCBI
16.	Jankun J and Skrzypczak-Jankun E: Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn. 119:410–417. 2009.PubMed/NCBI
17.	Repine T and Osswald M: Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. Clin Appl Thromb Hemost. 10:293–296. 2004. View Article : Google Scholar : PubMed/NCBI